Indivior PLC Ordinary Shares Total Liabilities

Latest as of September 2025: $1.62 Billion USD

Indivior PLC Ordinary Shares total liabilities. Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has total liabilities worth $1.62 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INDV asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Indivior PLC Ordinary Shares (2016–2024)

Total liabilities of Indivior PLC Ordinary Shares from 2016 to 2024. This chart illustrates how Indivior PLC Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data.

Indivior PLC Ordinary Shares Competitors by Total Liabilities

The table below lists competitors of Indivior PLC Ordinary Shares ranked by their total liabilities.

Company Country Total Liabilities
Wuxi Taiji Industry Co Ltd
SHG:600667
China CN¥25.74 Billion
Titan Cement International SA
BR:TITC
Belgium €1.37 Billion
T&S Communications Co Ltd
SHE:300570
China CN¥426.72 Million
Q2 Holdings
NYSE:QTWO
USA $324.96 Million
PT Pantai Indah Kapuk Dua Tbk
JK:PANI
Indonesia Rp19.33 Trillion
Mirion Technologies Inc
NYSE:MIR
USA $1.65 Billion
AUMOVIO N
XETRA:AMV0
Germany €9.56 Billion
Independent Bank
NASDAQ:INDB
USA $21.46 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Indivior PLC Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see INDV current and non-current assets.

Liquidity & Leverage Metrics

Indivior PLC Ordinary Shares Total Liabilities Ratios Explained

Indivior PLC Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -7.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Indivior PLC Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Indivior PLC Ordinary Shares (2016–2024)

The table below shows the annual total liabilities of Indivior PLC Ordinary Shares from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 $1.67 Billion -14.52%
2023-12-31 $1.95 Billion +12.97%
2022-12-31 $1.73 Billion +6.24%
2021-12-31 $1.63 Billion +12.20%
2020-12-31 $1.45 Billion +0.42%
2019-12-31 $1.44 Billion -2.57%
2018-12-31 $1.48 Billion -10.08%
2017-12-31 $1.65 Billion +9.51%
2016-12-31 $1.50 Billion --

About Indivior PLC Ordinary Shares

NASDAQ:INDV USA Drug Manufacturers - Specialty & Generic
Market Cap
$4.42 Billion
Market Cap Rank
#4041 Global
#1436 in USA
Share Price
$35.37
Change (1 day)
+0.34%
52-Week Range
$28.78 - $41.83
All Time High
$41.83
About

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more